We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hemogenyx Pharmaceuticals Plc | LSE:HEMO | London | Ordinary Share | GB00BYX3WZ24 | ORD GBP0.01 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.083 | -5.78% | 1.352 | 1.352 | 1.598 | 1.352 | 1.352 | 1.35 | 224,633 | 08:30:09 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | 0 | -6.69M | -0.0050 | -2.70 | 19.26M |
Date | Subject | Author | Discuss |
---|---|---|---|
09/5/2024 13:04 | next offering below 1p during summer Q3. no doubt! DILUTION MACHINE !! | marcus80 | |
09/5/2024 00:06 | For all the shares being SOLD by disappointed shareholders, there HAS to be a BUYER. Agreed..?And that BUYER, at this time of disillusionment, will be one of the appointed Market Makers.Who will be greedily mopping up what THEY have convinced us are assets of little value. (By their own manipulation).If you're not buying NOW, you never should have...Back your investment. Or cut your loss.Just never, ever cry | bahamarama | |
08/5/2024 13:37 | Looks like everyone has given up,it had to come didn’t it girls. | albert35911 | |
03/5/2024 14:46 | It don’t seem to be doing well today,much the same as most other days. | albert35911 | |
01/5/2024 02:33 | trade the spike to 3.5-4p on results xXTiPSXHEETSXx 5 month HOLD | purple11 | |
30/4/2024 10:39 | The speculation of prepping One patient for the clinical trial is pants The clinical trials will proceed with multiples of patients from all walks of life and Metabolisms The History of Car-t therapy has not been a 100% Success ! More positive outcomes from the younger Generation than Favoring The Older Generation ! although taking into consideration the Patients Prior lines of Treatment Will be Strictly monitored. ph1 formality of selected Patients Infusion and monitored over a period of time progressing t/ward P11 Pending Results ? | dreamtwister | |
29/4/2024 08:03 | O YES xXTiPSXHEETSXx see CR Thread | purple11 | |
29/4/2024 07:59 | Noted by Prevail in Sept RNS 👍 Mary Schaheen, President of Prevail Partners, stated: "Everyone at our fund is confident in the growth and success of Hemogenyx Pharmaceuticals as they develop CAR-T cells to target acute myeloid leukemia. Furthermore, Hemogenyx Pharmaceuticals has a seasoned management team with the expertise to accelerate the company to a significant value inflection point through the completion of its planned clinical trial." | purple11 | |
28/4/2024 15:40 | just watched the pod cast, im not sure but it came a cross as Dr Sandler HOPED to have the first patient infused for the start of the clinical Trial. Well I Hope they have more than one patient ? What Happens if that patient has withdrawal symptoms from the car-t side effects ? nope the interview has not hit the buy button so many un answered questions. The one question that needs to be addressed That the Fda highlighted & the reason for the Clinical trials hold was the purity/contamination of the Lentivirus ? The lentivirus is manufactured by Wuxi pharma china so a 3/4 week delivery window for a fresh batch of the lentivirus maybe the reason for the radio silence from Hemogenyx was that they had to or was told to produce a further 3 identical production runs before the clinical hold was lifted ! "sorry no room for errors" I Hope hemogenyx has found a alternative supplier of the lentivirus. | dreamtwister | |
27/4/2024 14:47 | How are your 2.3p PPP shares doing purple11?...... LOL Simples!...... :-) | nigoil | |
26/4/2024 21:03 | Hemo interviewToday 16:45 | purple11 | |
26/4/2024 14:56 | firming up up 6% still alot of interest in this stock as we approach a massive inflexion point with the trials gl xXTiPSXHEETSXx see CR Thread | purple11 | |
26/4/2024 14:05 | 100% correct albert35911.... :-) purple11 is the biggest offender! Simples!...... :-) | nigoil | |
26/4/2024 12:34 | tillywhizz lse ulver - good post , Prevail ain’t no naive muppets , they are a professional organisation who backed Hemos science & tossed a wedge in a lot higher than current stock price , I’m sure Vlad & Prevail are investigating all potential avenues for the benefit of Hemo & stockholders including Prevail . Noted by Prevail in Sept RNS Mary Schaheen, President of Prevail Partners, stated: "Everyone at our fund is confident in the growth and success of Hemogenyx Pharmaceuticals as they develop CAR-T cells to target acute myeloid leukemia. Furthermore, Hemogenyx Pharmaceuticals has a seasoned management team with the expertise to accelerate the company to a significant value inflection point through the completion of its planned clinical trial." Let’s see what next few months bring | purple11 | |
25/4/2024 15:25 | Nigoil…you have to laugh at their desperation. | albert35911 | |
25/4/2024 15:23 | How's your 2.3p PPP shares doing purple11?......LOL Don't follow purple11 advice, he was touting PPP as a bargain when they were 5p!........LOL Simples!.........;-) | nigoil | |
25/4/2024 15:09 | Hemo will be out of cash once again by the time the trial starts. | john henry | |
25/4/2024 14:50 | Another penny share that will bite the dust. | albert35911 | |
25/4/2024 14:28 | yeah,and so are phase 1 trials just around the corner positive news from that and were off to the races,theyll easilly be able to raise higher next time. | purple11 | |
25/4/2024 11:33 | theyve just done a large placing.plenty of money to last for the foreseeable. | purple11 | |
25/4/2024 07:36 | What is the CAB to 31/12/23 What is the remaining cash runway Anyone know? Looks like the burn is still £550k pcm | porky9 | |
25/4/2024 06:48 | Feel for long term holders. More money needed and no explanation as to where it's going to come from. A lot of talk of the past and very little on the future. | trying2trade |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions